Passage Bio Stock Investor Sentiment

PASG Stock  USD 1.13  0.46  68.66%   
Roughly 55% of Passage Bio's investor base is interested to short. The analysis of the overall investor sentiment regarding Passage Bio suggests that many traders are impartial. The current market sentiment, together with Passage Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use Passage Bio stock news signals to limit their universe of possible portfolio assets.
  

Passage Bio Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Passage Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at news.google.com         
PGs Board Needs an Overhaul - NRDC
Google News at Macroaxis
over a year ago at news.google.com         
Biological CP Market Future Growth Analysis Report till 2030 - Benzinga
Google News at Macroaxis
over a year ago at news.google.com         
Corn Syrup Market Global Updates Research Overviwe 2023 to 2030 - Benzinga
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Is Passage Bio In A Good Position To Deliver On Growth Plans?
Yahoo News
over a year ago at news.google.com         
2023 Bio-polyamide Market Top Players and Regions Shaping the Future - Benzinga
Google News at Macroaxis
over a year ago at news.google.com         
The Bio-Based Resins Market 2023 Competitive Landscape An ... - Benzinga
Google News at Macroaxis
over a year ago at bizjournals.com         
Lava Therapeutics is latest life sciences company to trim its workforce
bizjournals News
over a year ago at thelincolnianonline.com         
Passage Bio Price Target Lowered to 9.00 at Chardan Capital
news
over a year ago at thelincolnianonline.com         
Passage Bio Issues Quarterly Earnings Results
news
over a year ago at seekingalpha.com         
Passage Bio GAAP EPS of -0.44 beats by 0.03
seekingalpha News
over a year ago at globenewswire.com         
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
Macroaxis News: globenewswire.com
over a year ago at globenewswire.com         
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosido...
Macroaxis News: globenewswire.com
over a year ago at globenewswire.com         
Passage Bio to Participate in Upcoming Investor Conferences
Macroaxis News: globenewswire.com
over a year ago at www.macroaxis.com         
Acquisition by Sondhi Dolan of 48000 shares of Passage Bio subject to Rule 16b-3
Macroaxis News
over a year ago at globenewswire.com         
Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about Passage Bio that are available to investors today. That information is available publicly through Passage media outlets and privately through word of mouth or via Passage internal channels. However, regardless of the origin, that massive amount of Passage data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Passage Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Passage Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Passage Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Passage Bio alpha.

Passage Bio Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 63100 shares by Orbimed Advisors Llc of Passage Bio at 0.74 subject to Rule 16b-3
09/16/2024
2
Disposition of 111400 shares by Orbimed Advisors Llc of Passage Bio at 0.73 subject to Rule 16b-3
09/17/2024
3
Disposition of 25631 shares by Orbimed Advisors Llc of Passage Bio at 0.73 subject to Rule 16b-3
09/18/2024
4
Passage Bio to Present at Chardans 8th Annual Genetic Medicines Conference
09/23/2024
5
Acquisition by Kassberg Thomas Richard of 1741 shares of Passage Bio at 0.7 subject to Rule 16b-3
09/30/2024
6
Disposition of 30000 shares by Kathleen Borthwick of Passage Bio subject to Rule 16b-3
10/01/2024
7
Disposition of 50000 shares by Forman Mark S of Passage Bio subject to Rule 16b-3
10/03/2024
8
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
11/06/2024
9
Acquisition by Lynx1 Capital Management Lp of 259998 shares of Passage Bio at 0.5641 subject to Rule 16b-3
11/25/2024
10
Acquisition by Lynx1 Capital Management Lp of 167055 shares of Passage Bio at 0.7075 subject to Rule 16b-3
11/26/2024
11
Acquisition by Lynx1 Capital Management Lp of 29300 shares of Passage Bio at 0.6711 subject to Rule 16b-3
11/27/2024

Complementary Tools for Passage Stock analysis

When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk